Faculty mentor/PI email address
venkatar@rowan.edu
Keywords
SGLT2 inhibitors, dapagliflozin, empagliflozin, chronic kidney disease, type 2 diabetes mellitus, cardiorenal outcomes
Date of Presentation
5-6-2026 12:00 AM
Poster Abstract
SGLT2 inhibitors have emerged as a drug class with cardiorenal benefits beyond glycemic control in patients with type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD). This review compares two widely used SGLT2 inhibitors dapagliflozin and empagliflozin across efficacy, safety, and cost-effectiveness outcomes in patients with comorbid CKD and T2DM. A systematic literature search of PubMed, Scopus, and Embase yielded 10 final articles after screening. Both agents demonstrated comparable cardiorenal benefits, with dapagliflozin showing advantages in weight, blood pressure, and glycemic markers, while empagliflozin proved more cost-effective for CKD-specific disease management. Neither drug demonstrated significant safety concerns over placebo in large randomized controlled trials. Current evidence does not support one agent as definitively superior, and clinical selection should be guided by CKD stage, metabolic goals, and cost considerations.
Disciplines
Endocrine System Diseases
Included in
Beyond Glycemic Control: A Comparative Analysis of Dapagliflozin vs Empagliflozin
SGLT2 inhibitors have emerged as a drug class with cardiorenal benefits beyond glycemic control in patients with type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD). This review compares two widely used SGLT2 inhibitors dapagliflozin and empagliflozin across efficacy, safety, and cost-effectiveness outcomes in patients with comorbid CKD and T2DM. A systematic literature search of PubMed, Scopus, and Embase yielded 10 final articles after screening. Both agents demonstrated comparable cardiorenal benefits, with dapagliflozin showing advantages in weight, blood pressure, and glycemic markers, while empagliflozin proved more cost-effective for CKD-specific disease management. Neither drug demonstrated significant safety concerns over placebo in large randomized controlled trials. Current evidence does not support one agent as definitively superior, and clinical selection should be guided by CKD stage, metabolic goals, and cost considerations.